Citadel Advisors
RVMD icon

Citadel Advisors’s Revolution Medicines RVMD Stock Holding History

Citadel Advisors’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.4M Sell
167,600
-161,900
-49% -$23.6M ﹤0.01% 2036
2026
Q1 		$32M Buy
329,500
+316,900
+2,515% +$32M 0.01% 1793
2025
Q4 		$1M Sell
12,600
-143,000
-92% -$9.38M ﹤0.01% 7381
2025
Q3 		$7.27M Buy
155,600
+23,300
+18% +$912K ﹤0.01% 3729
2025
Q2 		$4.87M Buy
132,300
+27,200
+26% +$1.04M ﹤0.01% 4158
2025
Q1 		$3.72M Sell
105,100
-29,200
-22% -$1.19M ﹤0.01% 4382
2024
Q4 		$5.87M Buy
134,300
+18,900
+16% +$954K ﹤0.01% 3707
2024
Q3 		$5.23M Buy
115,400
+103,300
+854% +$4.5M ﹤0.01% 3863
2024
Q2 		$470K Buy
12,100
+1,100
+10% +$41.1K ﹤0.01% 8179
2024
Q1 		$355K Sell
11,000
-8,000
-42% -$237K ﹤0.01% 9123
2023
Q4 		$545K Buy
19,000
+4,100
+28% +$98.5K ﹤0.01% 7911
2023
Q3 		$412K Buy
14,900
+6,600
+80% +$196K ﹤0.01% 8497
2023
Q2 		$222K Hold
8,300
– – ﹤0.01% 9656
2023
Q1 		$180K Buy
8,300
+3,000
+57% +$73.9K ﹤0.01% 10363
2022
Q4 		$126K Buy
+5,300
New +$113K ﹤0.01% 10868
2022
Q1 		– Sell
-11,200
Closed -$282K – 14444
2021
Q4 		$282K Sell
11,200
-7,800
-41% -$220K ﹤0.01% 11057
2021
Q3 		$523K Buy
19,000
+11,700
+160% +$341K ﹤0.01% 9757
2021
Q2 		$232K Buy
+7,300
New +$255K ﹤0.01% 11840

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Citadel Advisors's RVMD Position: Q2 2026 in Review

Citadel Advisors increased its Revolution Medicines (RVMD) stake by 47% in Q2 2026, buying an estimated $27.7M and bringing the position to 589,906 shares worth $110M. The position accounts for 0.01% of the portfolio, ranked #906.

Citadel Advisors first reported a position in RVMD in Q1 2020 and has held it in 25 quarters since. 691 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Citadel Advisors held 589,906 shares of Revolution Medicines worth $110M as of Q2 2026.
  • Citadel Advisors bought 189,853 Revolution Medicines shares in Q2 2026, an estimated $27.7M.
  • Revolution Medicines made up 0.01% of Citadel Advisors's portfolio in Q2 2026, its #906 holding.
  • Citadel Advisors first reported a position in Revolution Medicines in Q1 2020 and has held it in 25 quarters since.
  • 691 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.